Trial Profile
A Phase IV Multi-Centric Post-Marketing Study Evaluating the Safety, Immunogenicity and EFFICACY of the Marketed Formulation of Hetero - Rituximab
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia; Granulomatosis with polyangiitis; Microscopic polyangiitis; Non-Hodgkin's lymphoma; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Hetero Drugs
- 25 Jun 2018 New trial record